匹多莫德联合氯雷他定治疗对小儿过敏性鼻炎症状评分、炎性因子及T细胞亚群的影响

The effects of pidotimod combined with loratadine on the symptom score,inflammatory factors,and T cell subsets in children with allergic rhinitis

目的研究分析匹多莫德联合氯雷他定治疗对小儿过敏性鼻炎症状评分、炎性因子及T细胞亚群的影响。方法2017年6月至2020年6月在南阳市第一人民医院石桥医院治疗的过敏性鼻炎患儿100例,按照治疗方法不同分为联合组(匹多莫德联合氯雷他定治疗)和基础组(氯雷他定治疗)各50例,比较两组患儿的治疗效果,不同时期总症状评分,治疗前后炎性因子及T细胞亚群变化情况。结果联合组治疗总有效率高于基础组(P<0.05);用药前两组总症状评分比较,差异无统计学意义(P>0.05),用药7、15 d后联合组总症状评分均明显低于基础组(P<0.05);用药后两组IL-4、IL-5水平均下降,TNF-α、IL-12均上升,且联合组变化程度优于对照组(P<0.05);两组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)水平均较用药前有不同程度上升,且联合组高于对照组(P<0.05);两组药物不良反应总发生率比较,差异无统计学意义(P>0.05)。结论匹多莫德联合氯雷他定治疗可有效提高过敏性鼻炎患儿的治疗效果,改善其症状评分、血清炎性因子与T淋巴细胞水平,安全性高,值得推广应用。

Objective To study and analyze the effect of pidotimod combined with loratadine on the symptom score,inflammatory factors,and T cell subsets of children with allergic rhinitis.Methods One hundred children with allergic rhinitis treated in our hospital from June 2017 to June 2020 were selected.According to different treatment methods,they were divided into a combination group treated with pidotimod combined with loratadine,and a basic group treated with loratadine,with 50 children in each group.The treatment effect,total symptom scores at different periods,changes in inflammatory factors and T cell subsets before and after treatment were compared between the two groups.Results The total efficacy of treatment in the combination group was higher than that of the basic group(P<0.05).Before medication,there was no statistically significant difference in the total symptom scores between the two groups(P>0.05).The total symptom score of the combination group was significantly lower than that of the basic group after 7 and 15 days of medication(P<0.05).After medication,the levels of interleukin 4(IL-4)and interleukin 5(IL-5)in the two groups were decreased.The levels of tumor necrosis factors(TNF-α)and interleukin 12(IL-12)were increased.The change in the combination group was better than that in the control group(P<0.05).The levels of CD3^(+),CD4^(+),CD4^(+)/CD8^(+) in the two groups were increased to various degrees after medication,and the level of the combined group was higher than that of the control group(P<0.05).There was no significant difference in the total incidence of adverse drug reactions between the two groups(P>0.05).Conclusion Pidotimod combined with loratadine therapy can effectively improve the therapeutic effect of children with allergic rhinitis,improve their symptom scores,serum inflammatory factors,and T lymphocyte levels.The safety level is high.It is worthy of promotion and application.